Novo Nordisk, a global healthcare company headquartered in Denmark, is to open a new production facility and warehouse in Odense, Denmark, following a 8.5 billion DKK investment. The site will cover 40,000m sq. and will accommodate multiple product types within rare disease treatments, such as for haemophilia.

Construction is scheduled to be completed in 2027 and the investment is expected to create 400 permanent jobs upon completion. During the construction process, up to 1,000 external employees will be working on-site.